Clascoterone vs Oxandrolone
FDA Approved vs Well Studied
monitor Mechanism-based · 51% Both Clascoterone and Oxandrolone carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects.
Molecular Data
Clascoterone Oxandrolone
Weight 388.54 Da 306.44 Da
Half-life Short topical (local action; rapidly metabolized to cortexolone) ~9-10 hours
Type Steroidal androgen receptor inhibitor 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3)
Key Benefits
Clascoterone
01 First-in-class topical androgen receptor inhibitor with FDA approval for acne
02 Blocks androgen action locally at the sebaceous gland and hair follicle without systemic hormonal effects
03 Suitable for both men and women, unlike systemic anti-androgens
04 Rapidly metabolized to inactive cortexolone, limiting systemic exposure
05 No clinically meaningful effects on systemic testosterone, DHT, or gonadotropin levels
06 Addresses the root androgen-driven pathology of both acne and androgenetic alopecia
Oxandrolone
01 Promotes lean muscle mass gains with minimal water retention
02 Supports recovery of lost body weight following surgery, trauma, or chronic illness
03 Reduces bone pain associated with osteoporosis and improves bone mineral density
04 Does not aromatize to estrogen, avoiding estrogen-related side effects
05 Well-studied safety profile in women, children, and burn patients
06 Enhances nitrogen retention and protein synthesis during caloric deficit
07 Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
08 Lower androgenic potency compared to most oral anabolic steroids
Side Effects
Clascoterone
Application site irritation, redness, or dryness
Pruritus (itching) at the application site
Contact dermatitis in sensitive individuals
Oxandrolone
HDL cholesterol suppression (dose-dependent, most significant lipid effect)
LDL cholesterol elevation
Mild hepatic stress (elevated liver enzymes ALT/AST)
Suppression of endogenous testosterone production
Mild headaches
Nausea or gastrointestinal discomfort
Changes in libido (increase or decrease depending on hormonal context)
Oily skin and mild acne
Contraindications
Known hypersensitivity to clascoterone or any component of the formulation
Women who are pregnant or planning to become pregnant (anti-androgens carry theoretical teratogenic risk)
Women who are breastfeeding (safety not established)
Active skin infections at the intended application site
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Nephrosis or nephrotic phase of nephritis
Hypercalcemia
Severe hepatic dysfunction or active liver disease
Hypersensitivity to oxandrolone or any formulation component
Research Evidence
Clascoterone Oxandrolone
Status FDA Approved Well Studied
References 4 studies 5 studies
Latest — September 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.